News
BPTH
--
0.00%
--
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers
Benzinga · 08/31 13:32
Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study
Zacks.com · 08/26 15:04
Bio-Path (BPTH) to Begin Clinical Study on Leukemia Drug
Zacks.com · 08/25 14:24
60 Biggest Movers From Yesterday
Gainers
Benzinga · 08/25 08:50
EDU, SESN and GOTU among mid-day movers
Gainers: Takung Art (NYSE:TKAT) +48%. Triple-S Management (NYSE:GTS) +45%. KLX Energy (NASDAQ:KLXE) +25%. New Oriental Education (NYSE:EDU) +26%. SkyWater Technology (NASDAQ:SKYT) +25%. Sentage (NASDAQ:SNTG) +24%. Bio-Path Holdings (NASDAQ:BPTH) +20%. TuSi...
Seekingalpha · 08/24 16:34
Mid-Day Market Update: Crude Oil Rises Over 2%; Theravance Biopharma Shares Slide
Midway through trading Tuesday, the Dow traded up 0.09% to 35,368.20 while the NASDAQ rose 0.40% to 15,001.95. The S&P also rose, gaining 0.14% to 4,486.01.
Benzinga · 08/24 16:17
Sector Update: Health Care Stocks Remain Lower Tuesday Afternoon
MT Newswires · 08/24 16:09
Triple-S Management, Bio-Path leads healthcare gainers; Theravance Biopharma, Vivos Therapeutics among major losers
Gainers: Triple-S Management (NYSE:GTS) +45%, Bio-Path (NASDAQ:BPTH) +21%, Reviva Pharmaceuticals (NASDAQ:RVPH) +21%, XTL Biopharmaceuticals (NASDAQ:XTLB) +13%, Protara Therapeutics (NASDAQ:TARA) +12%. Losers: Theravance Biopharma (NASDAQ:TBPH) -31%, Vivos...
Seekingalpha · 08/24 15:10
Why Bio-Path Holdings Shares Are Surging Higher Today
Bio-Path Holdings Inc (NASDAQ: BPTH) is surging higher Tuesday after the company announced the U.S Food and Drug Administration reviewed and cleared its Investigational New Drug application for BP1002 in refractory/relapsed acute myeloid leukemia patients.
Benzinga · 08/24 15:00
Sector Update: Health Care Stocks Falling in Tuesday Trading
MT Newswires · 08/24 13:19
Bio-Path Jumps as Leukemia Treatment Candidate Moves to Testing
The FDA approves the company's new investigational drug application, allowing it to move to Phase 1/1b clinical stage.
TheStreet.com · 08/24 12:33
JD, BILI and CARA among pre market gainers
Triple-S Management (NYSE:GTS) +44% to be acquired by GuideWell in an all-cash deal worth $900 million Bio-Path (NASDAQ:BPTH) +32% on FDA clearance of BP1002 application in acute myeloid leukemia Cara Therapeutics (NASDAQ:CARA) +21% and Vifor
Seekingalpha · 08/24 12:28
Benzinga Pro's Top 4 Stocks To Watch For Tuesday, Aug. 24, 2021: NVDA, SPLK, LOOP, BPTH
Today's 4 Stock Ideas:  NVIDIA (NVDA) - Shares have rallied over the all-important $200 level over the last few trading sessions. The stock was up about 17% since rebounding off the $190 level last
Benzinga · 08/24 12:17
Why Bio-Path Shares Are Moving Higher In Premarket Tuesday?
Benzinga · 08/24 12:15
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23)
Benzinga · 08/24 12:09
Bio-Path Holdings Announces FDA Clearance Of Investigational New Drug Application For BP1002 In Refractory/Relapsed Acute Myeloid Leukemia Patients
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today
Benzinga · 08/24 11:09
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed AML PatientsHOUSTON, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietar...
GlobeNewswire · 08/24 11:00
Bio-Path's Investigational New Drug Application for Leukemia Drug Candidate Gets FDA Clearance; Shares Rise Pre-Bell
MT Newswires · 08/24 07:49
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
Bio-Path Holdings Q2 EPS $(0.26) Beats $(0.39) Estimate
Bio-Path Holdings (NASDAQ:BPTH) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.39) by 33.33 percent. This is a 52.73 percent increase over losses of $(0.55) per share from
Benzinga · 08/13 11:17
Webull provides a variety of real-time BPTH stock news. You can receive the latest news about Bio-Path Holdings through multiple platforms. This information may help you make smarter investment decisions.
About BPTH
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The Company's drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. In vivo, the DNAbilize delivered antisense drug substances are systemically distributed across the body to allow for reduction or elimination of proteins in blood diseases and solid organs. Using DNAbilize as a platform for drug manufacturing, the Company has approximately three antisense drug candidates in development to treat a total of over five different cancer disease indications.